COLL experienced extraordinary growth with revenue surging 273% to $780.6M, driven by significant business expansion and operational scaling.
This represents a transformational year for COLL with revenue nearly quadrupling, suggesting either major acquisitions, new product launches, or dramatic market expansion that fundamentally changed the business size and scope. The approval of generic competition for Nucynta IR and the authorized generic agreement with Hikma indicate significant shifts in the company's competitive landscape and commercialization strategy.
COLL delivered exceptional financial performance with revenue growing 273% to $780.6M while maintaining strong profitability metrics - gross profit increased 259% and operating income rose 189%. The company strengthened its balance sheet with cash more than tripling to $231.3M and operating cash flow growing 61% to $329.3M, while reducing share buybacks by 58%, suggesting management is prioritizing cash preservation and reinvestment during this high-growth phase. The dramatic SG&A expense increase of 324% and interest expense surge of 301% indicate substantial investments in scaling operations and potentially debt-financed growth initiatives.
SG&A up 324.4% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Interest expense surged 301.3% — significant debt increase or rising rates materially impacting earnings.
Strong top-line growth of 272.8% — accelerating demand or successful expansion into new markets.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Cash position surged 227.7% — strong cash generation or capital raise providing significant financial cushion.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Net income grew 99.5% — bottom-line growth signals improving overall business health.
Operating cash flow surged 60.7% — exceptional cash generation, highest quality earnings signal.
Buyback activity reduced 58.2% — capital being redeployed elsewhere or cash conservation underway.
Current assets grew 43.4% — improving short-term liquidity or inventory/receivables build.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →